Denise Mann is a freelance health writer based in New York. With extensive experience covering a range of topics including medicine and healthcare, beauty and fashion, and public health, she brings a wealth of knowledge to her work, which has been featured in outlets such as HealthDay News and Reader's Digest. Denise's contributions to journalism have been recognized with multiple awards, including the Excellence in Women's Health Research Journalism Award and the 2011 National Newsmaker of the Year by the Community Anti-Drug Coalitions of America.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Denise Mann's coverage predominantly focuses on healthcare, pharmaceuticals, and scientific topics related to dermatology and skin conditions. The majority of her articles cite data or are based on press releases. She appears to be interested in reporting on the latest medical research, FDA approvals, and developments within the field of skincare.
When reaching out to Denise Mann with pitches or expert commentary, consider offering access to new research findings, exclusive insights into clinical trials for dermatological treatments or FDA approval processes. Providing access to experts who can offer unique perspectives on emerging trends in dermatology and skin care could also be well received by Denise.
Given that there is no specified geographic focus for Denise Mann's work, she may cover global developments within dermatology and skin care fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Denise Mann
Nemolizumab (Nemluvio, Galderma) provides meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), sustained through Week 52, according to new Phase 2 data presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference in Alexandria, VA. This Phase 2 multicenter, open-label study […]
By: Denise Mann
UCB is launching Wear It Out, a program created with and for people living with hidradenitis suppurativa (HS), plaque psoriasis, and psoriatic arthritis (PsA). Developed alongside patient advocates and artist Sophia Yeshi, the Wear It Out program showcases the everyday, often unseen decisions and compromises people make because of their conditions. For many people living […]
By: Denise Mann
Roflumilast cream 0.05% (Zoryve, Arcutis) performs well in infants with atopic dermatitis (AD), with results comparable to those seen in older kids, according to new research presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, NV. The Phase 2 INTEGUMENT-INFANT study assessed safety, tolerability, and exploratory in 101 infants with AD over four […]
The first-ever recipients of the Incyte Ingenuity Awards (IIA) in Hidradenitis Suppurativa (HS) are: The Association of Hidradenitis Suppurativa and Inflammatory Diseases received the up to $35,000 award for EASE-HS (Early Awareness and Symptom Education for Hidradenitis Suppurativa), a school-based initiative developed with Hope for HS Detroit and Henry Ford Health. The program helps students recognize early signs […]
By: Denise Mann
A new telehealth program may help teach melanoma patients and their children behaviors that will help prevent the onset of melanoma later in life. Yelena Wu, PhD, investigator at Huntsman Cancer Institute at the University of Utah (the U) and professor of dermatology at the U in Salt Lake City, UT, has found that her FLARE […]
The National Rosacea Society (NRS) has awarded grants for two new studies that seek to better understand the cause of this disorder. Arun Kumar, PhD, Assistant Professor at the University College Dublin School of Veterinary Medicine in Dublin. Ireland, was awarded $12,500 for his study, “Network pharmacology-guided dissection of dermal vascular inflammation and myeloid cell […]
By: Denise Mann
Lutikizumab performed well in adults and adolescents with HS, according to top-line results from the Phase 3 INTREPID study.
Many patients on glucagon-like peptide-1 receptor agonists (GLP-1RAs) experience significant changes in how they see themselves following weight loss, a new study shows. Among these patients, 78% said they no longer recognized themselves in the mirror after using a GLP-1 therapy. The survey, conducted by Talker Research on behalf of Revance, included 2,000 beauty-conscious Americans […]
By: Denise Mann
Dermoscopy Explainable Intelligence (DEXI), an artificial intelligence (AI) tool, may provide dermatologists with additional information to help assess whether skin lesions are cancerous and inform their clinical decisions, according to a study published in Mayo Clinic Proceedings. DEXI is a deep-learning tool trained on more than 66,000 annotated dermoscopy images. It assigns lesions a score from 0.0 to 10.0 based […]
By: Denise Mann
Intismeran autogene (intismeran), a novel investigational mRNA-based individualized neoantigen therapy (INT) and pembrolizumab (Keytruda, Merck) significantly reduced the risk of recurrence or death by 42% compared to pembrolizumab alone in patients with completely resected stage IIB-IV melanoma, according to results from the Phase 3 INTerpath-001 trial. The study, which was presented during Presidential Symposium I […]
